,

Guihong Liu1, Binbin Hu1, Tao Chen2

  • 1Department of Biotherapy, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Frontiers in oncology
|March 21, 2024
PubMed
概括

大约40%的食道状细胞癌 (ESCC) 患者在新辅助化学放射治疗 (nCRT) 和手术后复发. 在nCRT后的淋巴结状况影响复发时间和预后,阳性淋巴结导致更早的复发和更糟糕的结果.